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Abstract
Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor
prognosis. We propose that instead of continuing on bevacizumab, patients should switch to
treatment with Optune™, a novel antimitotic Tumor-Treating Fields (TTFields) therapy approved in the United States for newly diagnosed and recurrent GBM. This would reserve
bevacizumab for subsequent disease progression. In this case series, we describe 8 patients
with recurrent GBM who had disease progression on bevacizumab, discontinued bevacizumab treatment, and were treated with TTFields therapy alone. After subsequent radiographic or clinical progression, 5 patients were rechallenged with bevacizumab in a ‘pulse
dose’ fashion, an approach not previously described. Following treatment with TTFields therapy, median overall survival (OS) was 216 days (7.2 months). Median OS from last dose of
initial bevacizumab was 237 days (7.9 months), twice that of historical controls for bevacizumab failures, and median OS from the first dose of bevacizumab rechallenge was 172 days
(5.7 months). TTFields therapy was well tolerated, with a mean adherence rate of 74.2%
(range, 48.2–92.9%). These results support the use of TTFields therapy with pulse dose
bevacizumab as an option in patients with refractory GBM.
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Introduction

Glioblastoma (GBM) is the most common primary malignant neoplasm of the central
nervous system in adults [1], with a median overall survival (OS) of 14.6 months with standard chemoradiation [2]. Patients with recurrent GBM have limited treatment options [3].
Bevacizumab (Avastin®; Genentech, Inc., South San Francisco, Calif., USA), is an anti-VEGF
recombinant humanized monoclonal antibody approved in the United States as a single
agent for recurrent GBM [4]. Although radiographic responses are observed on MRI following treatment with bevacizumab [5–7], to date, no direct comparison between bevacizumab
and cytotoxic chemotherapy has been conducted, and it remains unclear if bevacizumab
improves OS in patients with recurrent GBM [6]. However, while on bevacizumab, patients
may derive clinical benefits that include decreased cerebral edema, improved neurologic
symptoms, and decreased corticosteroid use [7]. Once refractory to bevacizumab, patients
are unlikely to respond to subsequent regimens, whether they contain bevacizumab or not
[8], and inevitably relapse [9]. Median OS after bevacizumab failure has ranged from approximately 1.1 to 4.5 months regardless of treatment [10, 11].
OptuneTM (Novocure Inc., Portsmouth, N.H., USA), previously known as the NovoTTF100A System, a portable device delivering low-intensity intermediate-frequency (200 kHz)
alternating antimitotic tumor-treating fields (TTFields) via noninvasive transducer arrays, is
approved in the United States to treat adults with newly diagnosed as well as recurrent GBM
as an alternative to standard medical therapy [3]. A phase 3 study of TTFields therapy versus
physicians’ choice of chemotherapy in patients with recurrent GBM resulted in a median OS
of 6.6 months for TTFields therapy alone versus 6.0 months for chemotherapy (HR 0.86;
95% CI 0.66–1.12; p = 0.27), with more responses and fewer adverse events in the TTFields
therapy arm [3]. Post-hoc analyses of these data demonstrated that patients with bevacizumab-refractory GBM who were treated with TTFields therapy alone had a median OS of
6.0 months compared with 3.3 months for chemotherapy alone [11].
Rapid tumor regrowth or radiographic tumor-rebound phenomenon has been reported
after withdrawal of bevacizumab in patients with recurrent high-grade glioma, leading to an
accelerated clinical decline [10]. For this reason, many physicians are reluctant to discontinue bevacizumab even after bevacizumab failure has been well documented, leading to potential overtreatment. However, due to the antimitotic mechanism of action of TTFields therapy
[12], it is possible that patients with bevacizumab-refractory recurrent GBM will benefit
maximally from TTFields therapy after bevacizumab has been withdrawn and rapid tumor
proliferation sets in. Bevacizumab treatment can be resumed for subsequent radiographic
progression or worsening symptoms, due to either further disease progression or other inflammatory responses to TTFields-induced cell death. This case series describes the outcomes for 8 patients with bevacizumab-refractory GBM, who were treated with TTFields
therapy alone, then with concomitant pulse dose bevacizumab for subsequent radiographic
progression in 5 patients.

Patients were diagnosed with GBM from August 2011 to May 2013 and ranged in age
from 35 to 62 years; 5 were male.
Six of the 8 patients underwent standard treatment for GBM of maximal surgical resection followed by radiotherapy and temozolomide [2, 9]. Baseline demographics and characteristics of the patients are summarized in table 1. All patients received standard conformal
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radiation therapy (∼60 Gy) with concurrent temozolomide 75 mg/m2/day; 6 patients received from 1 to 10 cycles of high-dose maintenance temozolomide. One patient participated
in the phase 3 DCVax-L study for newly diagnosed GBM, receiving dendritic cell-based vaccine versus placebo. Another participated in the phase 3 EF-14 study testing TTFields therapy in newly diagnosed GBM, but was randomized to the control arm and received adjuvant
temozolomide alone.
Following their first disease recurrence, the patients received a number of different
treatments (table 1). Of the 8 patients, 7 had participated in clinical trials for their recurrent
GBM; 5 had participated in one clinical trial, and 2, in two trials. All received bevacizumab at
10 mg/kg every 2 weeks in addition to experimental agents where appropriate, which included rindopepimut, the anti-EGFRvIII mutation vaccine; dasatinib, a Src tyrosine kinase
inhibitor; and vorinostat, a histone deacetylase inhibitor.
Once unequivocal radiographic evidence of bevacizumab-refractory disease progression
using Response Assessment in Neuro-Oncology criteria was confirmed, bevacizumab was
discontinued and TTFields therapy was delivered using two pairs of noninvasive insulated
disposable arrays applied to the shaved scalp [3, 12]. For 7 patients, TTFields therapy was
administered third-line following disease progression on bevacizumab. One patient had surgery at disease recurrence followed by bevacizumab; therefore, TTFields therapy was administered fourth-line. One of the 8 patients received TTFields therapy for disease recurrence on a clinical trial.
Following radiographic progression while on TTFields therapy, 5 patients were rechallenged with bevacizumab 10 mg/kg every 2 weeks. Patients were monitored for radiographic and clinical progression; TTFields therapy and/or bevacizumab were discontinued at the
discretion of the treating physicians.
Survival data were collected between several time points: time from first day of
TTFields therapy to death, time from last dose of first round of bevacizumab to death, and
time from first dose of bevacizumab rechallenge until death. Patient deaths were confirmed
by hospital records, death certificate, and/or obituary notice.

Patient narratives for each of the 8 patients are presented below.
Patient No. 1, a male in his 40s, was diagnosed with a right frontal lobe GBM. He underwent near gross total resection (GTR) and received concomitant radiation therapy and temozolomide. Molecular testing revealed his tumor was MGMT negative. He subsequently
declined high-dose maintenance temozolomide and was treated with bevacizumab in a clinical trial. Disease recurrence was detected at month 13, and he subsequently received bevacizumab for 5 months before developing further progression at month 20 after diagnosis.
TTFields therapy was subsequently started for 4 months before further disease progression
was documented at month 25 after diagnosis, and the patient died at month 28. His adherence rate is not available, as this patient was lost to follow-up.
Patient No. 2, a male in his 40s, was diagnosed with right temporal lobe GBM. He underwent GTR and received radiation therapy and temozolomide. His tumor was MGMT negative and IDH negative. He received only 1 cycle of high-dose maintenance temozolomide due
to disease progression on MRI. The patient’s tumor recurred at month 5, and he received
bevacizumab from months 5 to 11. TTFields therapy was initiated at month 13 and continued until month 14; his adherence rate was 60.2%. Disease progression was detected at
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month 14. The patient was not rechallenged with bevacizumab due to an intracerebral hemorrhage, he died at month 14.
Patient No. 3, a female in her 50s, was diagnosed with right frontal lobe secondary recurrent GBM. She had a 30-year history of a prior low-grade glioma. She underwent nearGTR and received radiation therapy and temozolomide; however, due to subsequent myelosuppression, she did not receive high-dose maintenance temozolomide. Her tumor was IDH1
positive, EGFR amplification negative, loss of 10q negative, and 1p,19q co-deletion negative.
She was treated with bevacizumab from months 2 to 9, when disease recurrence was detected. TTFields therapy was started at month 9, and she was rechallenged with bevacizumab at
month 11. Her last MRI, at month 13, showed no disease progression. Both TTFields therapy
and bevacizumab were discontinued at month 14, due to intracerebral hemorrhage resulting
from a fall. The patient subsequently declined and died 16 months from her GBM diagnosis.
Her adherence rate to TTFields therapy was 84.0%.
Patient No. 4, a female in her 60s, was diagnosed with right frontal lobe GBM. Molecular
testing revealed her tumor to be MGMT positive. She underwent partial resection and received concomitant radiation therapy and temozolomide. She was enrolled in the EF-14
phase clinical trial of temozolomide therapy with and without TTFields therapy for newly
diagnosed GBM and was randomly assigned to the temozolomide alone arm. At disease progression at month 5, she was treated with bevacizumab in a clinical trial from months 6 to
17, when her tumor progressed. TTFields therapy was initiated at month 18, and the patient’s tumor progressed at month 22, when she was maintained on TTFields therapy and
rechallenged with bevacizumab. Both treatments were terminated at month 26, and the
patient died at month 27. Her adherence rate to TTFields therapy was 92.9%.
Patient No. 5, a male in his 30s, was diagnosed with left frontal lobe secondary GBM. The
patient did not receive radiation therapy since he had received radiation therapy for a prior
low-grade glioma 5 years prior to the GBM diagnosis. His tumor tested MGMT negative,
1p,19q co-deletion negative, EGFR amplification negative, IDH1 positive, and loss of
P16/CDKN 2A positive. He completed 6 cycles of high-dose maintenance temozolomide,
which was stopped due to disease progression on MRI. He was then treated with bevacizumab in a clinical trial from months 2 to 10, when his tumor progressed. TTFields was
started at month 12. Disease progression was documented at month 14, and he was rechallenged with bevacizumab. Further disease progression was documented at month 17. He
continued to receive TTFields treatment and bevacizumab until month 20, when he died. His
adherence rate to TTFields therapy was 75.9%.
Patient No. 6, a male in his 50s, was diagnosed with left frontal lobe GBM. He underwent
GTR and received radiation and temozolomide and completed 6 cycles of high-dose maintenance temozolomide, which was stopped due to disease progression on MRI. His tumor was
MGMT negative, EGFR amplification positive, PTEN negative, and IDH1/2 negative. The patient had disease recurrence diagnosed at month 9. Bevacizumab was administered from
months 10 to 13 before disease progression was noted. TTFields therapy was initiated at
month 14, and disease progression was detected at month 17. TTFields therapy was stopped
at month 18; his adherence rate was 48.2%. The patient was rechallenged with a single dose
of bevacizumab shortly prior to stopping TTFields, and died at month 15.
Patient No. 7, a male in his 40s, was diagnosed with left parietal lobe GBM. MGMT status
was not run due to an insufficient specimen quantity. He underwent GTR followed by concomitant radiation therapy and temozolomide as well as 10 cycles of high-dose temozolomide until disease progression on MRI. At month 13, the patient had disease progression and he was treated with bevacizumab in a clinical trial from months 14 to 24, when
disease progression was documented. TTFields therapy was started at month 24 and con-
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tinued until month 35, when it was stopped due to disease progression and a decline in the
patient’s performance status; his adherence rate was 73.2%. Further disease progression
was documented at month 26, and the patient was rechallenged with bevacizumab from this
date until month 36. The patient died at month 38.
Patient No. 8, a female in her 60s, was diagnosed with left frontal lobe GBM on December 16, 2011, and underwent GTR followed by concomitant radiation therapy and temozolomide. Her tumor was MGMT negative, EGFR amplification positive, IDH1 negative,
and 1p,19q co-deletion negative. She received 6 cycles of high-dose maintenance temozolomide, which was stopped due to disease progression on MRI. She was treated with
bevacizumab in a clinical trial. Disease recurrence was detected at month 10, and she received bevacizumab from months 10 until 19. TTFields therapy was initiated at month 16
and stopped at month 21; her adherence rate was 85.3%. The patient died at month 22. At
her last MRI at month 20, she had no disease progression.
Results

Our 8 patients had a median OS of 216 days (7.2 months) from first day of treatment
with TTFields therapy. Median OS from last dose of bevacizumab was 237 days (7.9 months;
table 2). Median OS from first dose of bevacizumab rechallenge was 172 days (5.7 months).
Median time on bevacizumab prior to treatment with TTFields therapy was 236.5 days
(7.9 months). Median time on TTFields therapy was 155 days (5.2 months), and median time
from start of TTFields therapy to radiographic progression was 80.5 days (2.7 months).
In 3 of the 5 patients rechallenged with bevacizumab, TTFields therapy was administered concurrently for up to 9 months, then discontinued prior to bevacizumab. One patient
received only a single dose of bevacizumab and 1 patient continued on both TTFields therapy and bevacizumab once bevacizumab was initiated.
Mean patient adherence rate to TTFields therapy was 74.2% (range, 48.2–92.9%), with
adherence defined as wearing the device at least 18 h per day. Patients highly adherent to
treatment – who were also those who received pulse dose bevacizumab – had the longest OS,
consistent with prior data. Patient No. 4 had an adherence rate of 92.9%; her time from first
day of TTFields therapy to death was 276 days (9.2 months) and, from first dose of bevacizumab rechallenge until death, 150 days (5.0 months). Patient No. 7, with an adherence
rate of 73.2%, had a time from first day of TTFields therapy to death of 406 days (13.5
months) and, from first dose of bevacizumab rechallenge until death, 349 days (11.6 months;
see fig. 1).

This set of cases describes a heavily pretreated population with bevacizumab-refractory
recurrent GBM with minimal therapeutic options. Following disease progression on bevacizumab, TTFields therapy alone was administered, stabilizing these patients and allowing
them to be rechallenged with bevacizumab once they became symptomatic.
Our 8 patients had a median OS of 7.9 months following progression on bevacizumab
and treatment with TTFields. These results compare favorably to what has been observed in
other studies for the same population of bevacizumab-refractory GBM. In a retrospective
study, patients who presented with bevacizumab-refractory recurrent GBM had a median OS
of 47.5 days (1.6 months); of 7 patients not restarted on bevacizumab, the median OS was 32
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days (1.1 months), in contrast to a median OS of 149 days (5.0 months) for the 3 patients
restarted on bevacizumab [10]. Our results in the 5 patients who were rechallenged with
bevacizumab show a similar prolonged OS, a median of 172 days (5.7 months) from the time
of bevacizumab rechallenge. In contrast, the 3 patients who were not rechallenged with
bevacizumab had a median survival of 11 days.
TTFields therapy is well tolerated with a favorable safety profile [13], and patients in
the phase 3 trial reported improved quality of life compared with patients receiving chemotherapy [3]. As a local treatment, the most commonly observed toxicity with TTFields therapy is skin irritation from the transducer arrays [3, 13]. In the phase 3 trial of TTFields therapy in recurrent GBM, higher adherence was found to correspond with greater survival benefit, as did age ≤60 years [11], both of which we found in this case series.
In this case series, we describe 8 patients with recurrent GBM for whom it was safe to
stop treatment with bevacizumab – despite the concern of possible rapid disease progression upon bevacizumab withdrawal –, effectively use TTFields therapy, and then rechallenge
with bevacizumab once they became symptomatic and/or had evidence of radiographic progression. This ‘pulse dose’ approach to bevacizumab administration, combined with
TTFields therapy, has not previously been described in this population, and its efficacy will
need to be investigated further in a prospective clinical study. In the meantime, the results
from this limited series suggest that this approach is well tolerated and may be considered
an option in these very refractory patients.
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Table 1. Patient baseline demographics and characteristics
Patient No.
1

2

3

4

5

6

7

8

Gender

Male

Male

Female

Female

Male

Male

Male

Female

Age at diagnosis,
years

49

48

52

60

35

51

48

62

GBM de novo

Yes

Yes

No1

Yes

No2

Yes

Yes

Yes

MGMT

Negative

Negative

Positive

Negative

Negative

Negative

IDH1 and/or IDH2

Negative

Molecular testing

–

Positive

–

Positive

Negative

Insufficient
specimen
–

EGFR amplification –

–

Negative

–

Negative

Positive

–

Positive

1p,19q
co-deletion
Other

–

–

Negative

–

Negative

–

–

Negative

–

–

Loss of 10q
negative

–

Loss of P16/
PTEN
CDKN2A positive negative

–

–

Tumor
location

Right frontal Right temporal Right frontal Right frontal Left frontal
lobe
lobe
lobe
lobe
lobe

Left frontal Left parietal
lobe
lobe

Left frontal
lobe

Resection

Near GTR

GTR

Near GTR

Partial

GTR

GTR

GTR

GTR

XRT

Yes

Yes

Yes

63 Gy

None due to
60 Gy
previous XRT for
low-grade glioma

63 Gy

60 Gy

Concurrent
temozolomide
(75 mg/m2/day)

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Negative

Prior low-grade glioma in the 1980s. 2 Prior low-grade glioma in 2007. GTR = Gross total resection; TMZ = temozolomide; NCCTG = North
Central Cancer Treatment Group.
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Table 2. Duration of bevacizumab and TTFields therapy (TTF) and OS by patient
Treatment duration

Initial duration of bevacizumab treatment, days
TTF for recurrence on trial
TTF line of therapy
Duration on TTF, days
Time on TTF until radiographic progression, days
TTF adherence, %
Time from first day of TTF to death, days
Time from last dose of first round of bevacizumab to death, days
Patients rechallenged with bevacizumab
Time from first dose until death, days
Survival from diagnosis until death, days
Patients not rechallenged with bevacizumab
Time from survival from last day of TTF until death, days
Survival from diagnosis until death, days

Patient No.
1

2

3

4

5

6

7

8

154
No
Third
80
112
N/A3
211
246

182
Yes1
Third
60
55
60.2
614
103

221
No
Third
157
N/A2
84.0
221
228

315
No
Third
252
124
92.9
276
304

276
No
Fourth
235
55
75.9
253
295

91
No
Third
154
105
48.2
169
182

322
No
Third
321
56
73.2
406
411

252
No
Third
153
153
85.3
165
185

N/A5
–

N/A4
–

172
510

150
810

197
604

366
569

349
1,133

N/A7
–

131
837

1
461

–
–

–
–

–
–

–
–

–
–

11
661

1 Novocure and genomic analysis study. 2 No progression documented on MRI; bevacizumab initiated for functional decline. 3 Patient lost to
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Fig. 1. Radiographic appearance of bevacizumab-refractory GBM treated with TTFields and subsequently
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rechallenged with bevacizumab. Representative pictures of serial gadolinium contrast-enhanced brain
MRI scans of patients No. 4 and No. 7 are shown. Colored bars denote time line of TTFields therapy and
bevacizumab rechallenge. The time frame is in months, starting from the first documented radiographic
diagnosis of bevacizumab-refractory GBM. Patient No. 4 demonstrated an initial response to TTFields at 2
months but progressed radiographically at 4 months. Upon rechallenge with bevacizumab, this patient’s
GBM demonstrated a radiographic response to bevacizumab again. Patient No. 7 did not demonstrate
radiographic response to TTFields in the first 2 months. However, this patient had a durable radiographic
response to bevacizumab rechallenge while continuing on with TTFields therapy.

